GC Aesthetics® Announces Growth and Expansion in Brazil
GC Aesthetics®, Inc. (GCA), a privately-held medical technology company providing Women Healthcare Aesthetic and Reconstructive Solutions, has announced today, its growth and expansion plans for the Brazilian market, the second largest Breast Augmentation market in the world.
GC Aesthetics® has been executing an ambitious journey repositioning the brand and portfolio to offer a smart, unique, and clinically proven safe range of products to meet the needs of Brazilian women and surgeons.
The Brazilian growth strategy includes 2 main pillars. First, the commercialization of all GC Aesthetics® products and solutions designed to support the best outcome for women's breast enhancement journey, before, during and after surgery. This unique portfolio not only stands out in today’s industry but is aligned with the company leadership position and growing plans evolving from Breast Implant Manufacturers to Solution Providers.
The Brazilian revenue growth of GC Aesthetics® is also linked to the ANVISA certificate (Brazilian Health Regulatory Agency) just obtained for the re-introduction of The Round Collection™ Breast Implants. This unique microtextured surface breast implant has been the preferred option by surgeons in Brazil: 99% of surveyed Plastic Surgeons consider The Round Collection™ as the trustable product in terms of safety and performance.
“According to our most recent survey, long-term proven safety & the unique type of micro texture are the 2 top reasons Brazilian Plastic Surgeons prefer The Round Collection Implants against competitors. We are beyond excited to be back in Brazil with this product and offer Surgeons and Patients, a proven long-term, safe and reliable medical device. Pre-orders of this product have exceeded what we had planned, and we are looking forward to a very bright, leading future in Brazil and in the world” – said Carlos Reis Pinto, CEO of GC Aesthetics®
“At GCA®, we are dedicated to advancing the science of medical aesthetics and delivering exceptional clinical, operational and commercial performance to be the preferred partner of surgeons and physicians worldwide, we are excited for The Round Collection™ re-entry in Brazil and are excited of presenting our brand as ONE GCA” – mentioned Ron Cosmas, CCO of GCA®.
GC Aesthetics® will be presenting the re-introduction of this product at the Jornada Paulista de Cirurgia Plástica, held from June 15th to the 18th at the WTC São Paulo, Brazil. Engineered and designed for performanceThe Round Collection™ breast implants have an unparalled long-term safety profile. The Round Collection™ by GC Aesthetics® is part of the largest European long-term clinical study for breast implants with exceptional results at 10 years and recently had data published in a one-of-a-kind 17 year patient follow-up with remarkable patient satisfaction.
About GC Aesthetics
GC Aesthetics is a long-established global medical technology company that develops, manufactures and markets a comprehensive range of proprietary aesthetic products that empower patients to feel confident and secure in their personal life journey.
Throughout its 40-year history, GCA has been dedicated to advancing the science of medical aesthetics and delivering high-quality breast implants for breast augmentation and breast reconstructive surgery. We have sold more than 3 million implants across 70 countries, and our products are supported by published 10-year clinical data demonstrating compelling safety and clinical effectiveness.
The company’s vertically integrated strategy enables exceptional clinical, operational and commercial performance, which allows GCA to provide competitively differentiated products to surgeons and patients. Through a culture of continuous innovation and dedication to customer-responsiveness, GCA has established itself as a leading provider of medical aesthetics solutions and the partner-of-choice for patients seeking to improve their lives.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220615005653/en/
Contact information
Fara Naomi Macias, Chief Marketing Officer
faramacias@gcaesthetics.com
About Business Wire
Business Wire(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Long Tale Games Relaunches Life is Feudal: MMO on Steam With a Significant Event, the Balance Restoration Campaign18.4.2024 14:00:00 CEST | Press release
Long Tale Games (LTG) announces the Steam relaunch of Life is Feudal: MMO. To show appreciation to the game's community, the publisher is launching a special event aimed at the game's original players, the Balance Restoration Campaign. Players who have made any purchases during the previous Life is Feudal: MMO round will receive special LiF Coins that can be exchanged for a subscription to the game. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240418169927/en/ (Graphic: Business Wire) Since the relaunch in June 2023, Life is Feudal: MMO has transitioned to a subscription-based model, removing all pay-to-win features. This shift ensures a level playing field for all players, fostering fairness as success in the game now fully depends on the player's skill and effort, creating a more engaging environment. Until now, the game has only been distributed through the publisher's (LTG.com) own personal gaming platform. However, wi
Newmont Publishes 2023 Sustainability Report and 2023 Tax & Royalties Report18.4.2024 14:00:00 CEST | Press release
Newmont Corporation (NYSE: NEM, TSX: NGT, ASX: NEM, PNGX: NEM) today published its 2023 Sustainability Report and its 2023 Taxes and Royalties Contributions Report. The reports highlight the company’s material ESG and socio-economic contributions over the past year. This year marks the 20th anniversary for Newmont’s Annual Sustainability Report, representing a milestone for the company as a longstanding industry leader in sustainability. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240417961090/en/ Newmont's 2023 Sustainability Report (Graphic: Business Wire) "Our 2023 Sustainability Report demonstrates our unwavering commitment to responsible resource management and the integral role that Newmont plays in creating a more sustainable future," said Newmont Chief Safety and Sustainability Officer Suzy Retallack. "We recognize the responsibility we have to mitigate our environmental impact and make a difference in the areas w
Vertex Announces Advancements of Suzetrigine (VX-548) in Acute and Neuropathic Pain18.4.2024 14:00:00 CEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced important advancements across its suzetrigine pain program, which has the potential to be the first new class of medicine for acute and neuropathic pain in more than two decades. Suzetrigine is an oral selective NaV1.8 pain signal inhibitor (formerly known as VX-548). Following the positive Phase 3 results in acute pain announced in January 2024, the Food and Drug Administration (FDA) has granted a rolling New Drug Application (NDA) submission for suzetrigine in moderate-to-severe acute pain. Vertex has started the rolling submission process and is on track to complete the submission in the second quarter of 2024. Suzetrigine was previously granted FDA Fast Track and Breakthrough Therapy designations in moderate-to-severe acute pain. In neuropathic pain, Vertex released positive results from its Phase 2 study in December 2023 and recently completed a successful end-of-phase 2 meeting with the FDA. Vertex is now preparin
MediaCo Acquires Estrella Media’s Content and Digital Operations18.4.2024 13:36:00 CEST | Press release
MediaCo Holding Inc. (Nasdaq: MDIA) (“MediaCo”) today announced that it has acquired all of Estrella Media’s network, content, digital, and commercial operations. Among the Estrella Media brands joining MediaCo are the EstrellaTV network and its influential linear and digital video content business, and Estrella Media’s expansive digital channels, including its four FAST channels – EstrellaTV, Estrella News, Cine EstrellaTV, and Estrella Games – and the EstrellaTV app. The transaction closed on April 17, 2024. MediaCo, which operates marquee urban radio stations HOT 97 and WBLS 107.5 in New York City, will be adding Estrella Media’s Spanish-language video, audio, and digital content operations under the same umbrella. This transaction will also allow MediaCo to reach the established audiences of Estrella Media’s market-leading Regional Mexican radio stations, including Que Buena Los Angeles, home of the Don Cheto Al Aire nationally syndicated morning radio show, La Raza in Houston and
TriLink BioTechnologies ® Announces New San Diego Facility for Late Phase mRNA Drug Substance Production18.4.2024 13:36:00 CEST | Press release
TriLink BioTechnologies (TriLink®), a Maravai LifeSciences company (NASDAQ: MRVI) and global provider of life science reagents and services, has announced the grand opening of its new cGMP mRNA manufacturing facility. The 32,000-square-foot facility was specifically designed for mRNA manufacturing to support late-phase drug developers from Phase 2 to commercialization via TriLink’s robust mRNA manufacturing capabilities. The milestone opening is expected to help advance the field of mRNA-based medicine as developers flock to leverage the promising modality for a growing list of indications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240418722567/en/ TriLink BioTechnologies® Cuts Ribbon on New San Diego Facility for Late Phase mRNA Drug Substance Production (Photo: TriLink BioTechnologies®) Located in the Sorrento Valley area of San Diego, the facility features individual Grade C cleanroom suites for mRNA manufacturing, i